Specifically, EGF can induce PD-L1 N-linked glycosylation in basal-like breast cancer, leading to the inhibition of PD-L1 polyubiquitination and subsequent proteasomal degradation by antagonizing the binding of GSK3β [44]. Here, CD274 is linked to breast cancer.